|Mr. Jack Phillips||CEO, Pres & Director||289.43k||N/A||1966|
|Mr. Steve Reichling||CFO, Chief Accounting Officer & Sec.||340k||N/A||1978|
|Mr. Lawrence Mehren||Advisor||500k||N/A||1966|
|Mr. Ron Price||Chief Commercial Officer of Americas||240k||N/A||1964|
|Laura Pierson||Investor Relations Officer||N/A||N/A||N/A|
|Mr. Michael Bridge||Sr. VP & Gen. Counsel||N/A||N/A||N/A|
|Ms. Gretchen Strohminger||Sr. VP and Head of HR & Culture||N/A||N/A||N/A|
|Ms. Constance Bridges||Sr. VP and Head of Regulatory & Quality||N/A||N/A||N/A|
|Mr. Cherif Bousselham||Sr. VP & Head of Sales - EMEA||N/A||N/A||N/A|
|Ms. Laura Costa||Sr. VP & Head of Global Customer Support||N/A||N/A||N/A|
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
Accelerate Diagnostics, Inc.’s ISS Governance QualityScore as of November 2, 2019 is 5. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 2; Compensation: 10.